NASDAQ:JNCE - Jounce Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.80 -0.95 (-20.00 %)
(As of 01/21/2019 03:10 AM ET)
Previous Close$3.80
Today's Range$3.77 - $4.77
52-Week Range$2.66 - $29.25
Volume697,058 shs
Average Volume308,507 shs
Market Capitalization$124.26 million
P/E Ratio-6.67
Dividend YieldN/A
Beta3.81
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$71.64 million
Book Value$5.18 per share

Profitability

Net Income$-16,440,000.00

Miscellaneous

Employees112
Market Cap$124.26 million
OptionableOptionable

Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.23) EPS for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.11. The firm had revenue of $14.53 million for the quarter, compared to analysts' expectations of $12.80 million. Jounce Therapeutics had a negative net margin of 59.74% and a negative return on equity of 29.58%. View Jounce Therapeutics' Earnings History.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Jounce Therapeutics.

What guidance has Jounce Therapeutics issued on next quarter's earnings?

Jounce Therapeutics updated its FY 2018 earnings guidance on Tuesday, November, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50-60 million, compared to the consensus revenue estimate of $56.46 million.

What price target have analysts set for JNCE?

6 Wall Street analysts have issued 1 year price targets for Jounce Therapeutics' stock. Their predictions range from $10.00 to $20.00. On average, they expect Jounce Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 242.1% from the stock's current price. View Analyst Price Targets for Jounce Therapeutics.

What is the consensus analysts' recommendation for Jounce Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

Has Jounce Therapeutics been receiving favorable news coverage?

News articles about JNCE stock have trended somewhat negative on Monday, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Jounce Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 685,595 shares, a decrease of 43.9% from the December 14th total of 1,221,600 shares. Based on an average trading volume of 514,155 shares, the days-to-cover ratio is currently 1.3 days. Approximately 4.7% of the shares of the company are sold short. View Jounce Therapeutics' Current Options Chain.

Who are some of Jounce Therapeutics' key competitors?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 59)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 53)
  • Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 58)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.10%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

Which institutional investors are buying Jounce Therapeutics stock?

JNCE stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc, Hugh M Cole and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $3.80.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $124.26 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is http://www.jouncetx.com.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  321
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel